Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry. Register now to see our 7 Best Stocks for the Next 30 Days report - free today! Amgen AMGN, in a press release, dismissed recent concerns that its obesity candidate, MariTide, may cause loss of bone mineral density (“BMD”). Some analysts at a global financial services firm claimed that a review of phase I data on MariTide showed that the candidate led to a drop in BMD, which is a measure of the amount of minerals in bones. Reduced BMD can increase the risk of fractures. The data from the phase I study were published in a journal in February. The concerns resulted in a sharp decline in the stock price on Tuesday. Amgen, in the latest press release, said there was no connection between the administration of MariTide and BMD changes. The phase I data do not indicate any concerns related to bone safety. The stock recovered on Wednesday after Amgen's statement. Top-line 52-week data
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024 [Yahoo! Finance]Yahoo! Finance
- AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024PR Newswire
- EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder [Yahoo! Finance]Yahoo! Finance
- Amgen Inc. (NASDAQ: AMGN) is now covered by analysts at Citigroup Inc.. They set a "neutral" rating and a $335.00 price target on the stock.MarketBeat
- MOORE LAW ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRMPR Newswire
AMGN
Earnings
- 10/30/24 - Beat
AMGN
Sec Filings
- 11/6/24 - Form 4
- 11/6/24 - Form 4
- 11/6/24 - Form 4
- AMGN's page on the SEC website